Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Authors: Christopher M. Blanchette, Benjamin Gutierrez, Keith Friend
Journal: Annals of Internal Medicine (2014)

Letters21 January 2014Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney DiseaseChristopher M. Blanchette, PhD, MBA, Benjamin Gutierrez, PhD, and Keith Friend, MDChristopher M. Blanchette, PhD, MBAFrom Otsuka America Pharmaceutical, Princeton, New Jersey.Search for more papers by this author, Benjamin Gutierrez, PhDFrom Otsuka America Pharmaceutical, Princeton, New Jersey.Search for more papers by this author, and Keith Friend, MDFrom Otsuka America Pharmaceutical, Princeton, New Jersey.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5001-6 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We acknowledge Erickson and colleagues’ (1) effort to study ADPKD, for which no approved treatment is available. Compared with placebo, tolvaptan was found to slow the increase in total kidney volume and decline in kidney function and led to more incidents of aquaresis (excretion of electrolyte-free water) and hepatic adverse events over 3 years in patients with this condition (2). Although a cost-effectiveness analysis of tolvaptan is necessary, it is premature to complete at this time because several key data points are unknown.Tolvaptan is available in the United States (3) but is not approved for the ...References1. Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med. 2013;159:382-9. [PMID: 24042366] LinkGoogle Scholar2. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407-18. [PMID: 23121377] CrossrefMedlineGoogle Scholar3. Otsuka Pharmaceutical. Full Prescribing Information for Tolvaptan. 2012. Accessed at www.accessdata.fda.gov/drugsatfda_docs/label/2012/022275s007lbl.pdf on 9 October 2013. Google Scholar4. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1:148-57. [PMID: 17699202] CrossrefMedlineGoogle Scholar5. Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003;63:678-85. [PMID: 12631134] CrossrefMedlineGoogle Scholar6. Thong KM, Ong AC. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM. 2013;106:639-46. [PMID: 23587574] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Christopher M. Blanchette, PhD, MBA; Benjamin Gutierrez, PhD; Keith Friend, MDAffiliations: From Otsuka America Pharmaceutical, Princeton, New Jersey.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L13-1105. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease James Lineen , David M.J. Naimark , and Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease James Lineen , David M.J. Naimark , and Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Kevin F. Erickson , Glenn M. Chertow , and Jeremy D. Goldhaber-Fiebert Metrics Cited byTolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management 21 January 2014Volume 160, Issue 2Page: 142-143KeywordsAdverse eventsConflicts of interestDisclosureExcretionKidney stonesKidneysPolycystic kidney diseaseRenal diseasesSafetySafety studies ePublished: 21 January 2014 Issue Published: 21 January 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...